Core Viewpoint - The financial performance of QuanFeng Automotive shows a trend of increasing revenue but persistent net losses, indicating potential challenges in profitability despite revenue growth [1][2][3]. Financial Performance Summary - The company's operating revenue for 2022, 2023, and 2024 was 1.745 billion, 2.134 billion, and 2.303 billion RMB respectively, reflecting a growth trend [1]. - The net profit attributable to shareholders for the same years was -154 million, -565 million, and -517 million RMB, indicating ongoing losses [1]. - The net profit after deducting non-recurring gains and losses was -187 million, -546 million, and -522 million RMB for 2022, 2023, and 2024 respectively [1]. - The net cash flow from operating activities improved from -527 million in 2022 to 138 million in 2024, showing a positive shift in cash flow [1]. Q1 2025 Performance - In the first quarter of 2025, the company achieved an operating revenue of 601 million RMB, a year-on-year increase of 19.36% [2][3]. - The net profit attributable to shareholders for Q1 2025 was -90 million RMB, an improvement from -141 million RMB in the same period of the previous year [2][3]. - The net cash flow from operating activities for Q1 2025 was -115 million RMB, slightly worse than -112 million RMB in Q1 2024 [2][3]. Fundraising Activities - QuanFeng Automotive raised a total of 480 million RMB through its initial public offering, with net proceeds of approximately 452 million RMB allocated for production and working capital [4]. - The company conducted a non-public offering in 2022, raising approximately 1.192 billion RMB, with net proceeds of about 1.178 billion RMB after expenses [5]. - The company plans to issue shares to a related party, Derun Holdings, with a total fundraising amount not exceeding 200 million RMB, aimed at supplementing working capital and repaying bank loans [7].

北京国枫律师事务所 关于四川和邦生物科技股份有限公司 申请公开发行可转换公司债券的 补充法律意见书之二 国枫律证字[2022]AN259-9 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦７层 邮编:100005 电话（Tel）: 010-88004488/66090088 传真(Fax):010-66090016 北京国枫律师事务所 关于四川和邦生物科技股份有限公司 申请公开发行可转换公司债券的 补充法律意见书之二 国枫律证字[2022|AN259-9号 致:四川和邦生物科技股份有限公司（发行人） 根据本所与发行人签订的《律师服务协议书》,本所接受发行人委托,为发 行人本次发行项目提供专项法律服务。本所已根据相关法律、法规、规章和规范 性文件的规定并按照律师行业公认的业务标准、道德规范和勤勉尽责精神,对发 行人提供的文件和有关事实进行了查验,并就发行人本次公开发行可转债事宜出 具了《北京国枫律师事务所关于四川和邦生物科技股份有限公司申请公开发行可 转换公司债券的法律意见书》《北京国枫律师事务所关于四川和邦生物科技股份 有限公司申 ...